Samsung Bioepis files for IPR of Regeneron’s US 10,888,601, relating to Eylea® (aflibercept)

Feb 10, 2023

Samsung Bioepis filed a petition for inter partes review of Regeneron’s US 10,888,601, relating to Eylea® (aflibercept).  In August 2022, Regeneron sued Viatris (Mylan) for infringement of 24 patents relating to Eylea, including the‘601 patent.

Print Page Mail Article